# Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

> **NCT00575952** · PHASE1 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 27 (actual)

## Conditions studied

- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Mixed Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Squamous Cell Carcinoma
- Endometrial Undifferentiated Carcinoma
- Recurrent Uterine Corpus Carcinoma
- Stage IIIA Uterine Corpus Cancer
- Stage IIIC Uterine Corpus Cancer
- Stage IVA Uterine Corpus Cancer
- Stage IVB Uterine Corpus Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Doxorubicin Hydrochloride
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT00575952
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-17
- **Primary completion:** 2016-07-16
- **Final completion:** 2016-07-16
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00575952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00575952, "Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00575952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*